BPC-157 - Hemi Pharma

The roots of BPC-157 trace back to the early 1990s, when Croatian scientist Predrag Sikiric began formal investigation into its properties. It was created as a synthetic version of a peptide fragment naturally found in human gastric secretions and was noted for its ability to support tissue regeneration. Backed by Pliva Pharmaceuticals until 2005, the compound was later eyed by Merck, though no acquisition followed. Since then, BPC-157 entered the research chemical space, with Slovenian firm Diagen emerging as a principal source.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC-157 by Hemi Pharma, consult with your doctor or healthcare professional.